Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus

Phase 1

Completed

Conditions: CIS
Barrett's Esophagus
High Grade Dysplasia

Interventions: Drug: HPPH

First Posted Date: 2010-11-08

Last Posted Date: 2014-01-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 18

Registration Number: NCT01236443

Locations: 🇺🇸
Roswell Park cancer institute, Buffalo, New York, United States

Exercise Intervention in Breast Cancer Patients With Treatment-Induced Arthralgia

Not Applicable

Completed

Conditions: Breast Cancer
Arthralgia

Interventions: Behavioral: Exercising block

First Posted Date: 2010-11-07

Last Posted Date: 2012-04-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 27

Registration Number: NCT01236417

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Brody Belt - Alternative Method of Securing a Patient's Urinary Drainage Bag

Not Applicable

Terminated

Conditions: Quality of Life

Interventions: Procedure: Quality of life

First Posted Date: 2010-10-27

Last Posted Date: 2017-12-08

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 12

Registration Number: NCT01228864

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer

Phase 2

Terminated

Conditions: Stage IV Rectal Cancer
Stage IV Colon Cancer

Interventions: Drug: leucovorin calcium
Biological: bevacizumab
Dietary Supplement: cholecalciferol
Drug: fluorouracil
Drug: oxaliplatin
Other: pharmacological study

First Posted Date: 2010-09-10

Last Posted Date: 2014-07-21

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 10

Registration Number: NCT01198548

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer

Phase 2

Completed

Conditions: Stage IIIB Esophageal Adenocarcinoma
Stage IIIC Esophageal Squamous Cell Carcinoma
Stage IIIC Gastric Cancer
Stage IV Esophageal Adenocarcinoma
Stage IV Esophageal Squamous Cell Carcinoma
Undifferentiated Gastric Carcinoma
Adenocarcinoma of the Gastroesophageal Junction
Esophageal Undifferentiated Carcinoma
Gastric Adenocarcinoma
Recurrent Esophageal Adenocarcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Oxaliplatin
Drug: Pralatrexate

First Posted Date: 2010-08-10

Last Posted Date: 2017-12-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 35

Registration Number: NCT01178944

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Rochester General Hospital, Rochester, New York, United States

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Phase 1

Terminated

Conditions: Adenocarcinoma of the Prostate
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer
Prostate Cancer

Interventions: Drug: vorinostat
Drug: temsirolimus
Other: laboratory biomarker analysis
Procedure: positron emission tomography/computed tomography

First Posted Date: 2010-08-03

Last Posted Date: 2022-10-03

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 13

Registration Number: NCT01174199

Locations: 🇺🇸
The Sydney Kimmel Comprehensive Center at John Hopkins, Baltimore, Maryland, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx

Phase 1

Completed

Conditions: Dysplasia
Carcinoma of the Oral Cavity
Carcinoma of the Oropharynx

Interventions: Drug: HPPH

First Posted Date: 2010-06-09

Last Posted Date: 2018-10-16

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 29

Registration Number: NCT01140178

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery

Not Applicable

Terminated

Conditions: Stage I Bladder Cancer
Stage 0 Bladder Cancer
Recurrent Bladder Cancer
Transitional Cell Carcinoma of the Bladder
Stage II Bladder Cancer

Interventions: Drug: broccoli sprout extract
Other: Mango Juice
Other: laboratory biomarker analysis

First Posted Date: 2010-04-21

Last Posted Date: 2017-06-26

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 7

Registration Number: NCT01108003

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

Phase 1

Terminated

Conditions: Adult Solid Neoplasm

Interventions: Dietary Supplement: Calcitriol
Drug: Cisplatin
Drug: Gemcitabine Hydrochloride
Other: Pharmacological Study

First Posted Date: 2010-03-25

Last Posted Date: 2016-01-12

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 14

Registration Number: NCT01093092

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Clear Cell Sarcoma of the Kidney
Recurrent Renal Cell Carcinoma
Stage IV Renal Cell Cancer
Stage III Renal Cell Cancer

Interventions: Drug: Dalteparin
Other: Pharmacological Study
Drug: Sunitinib Malate

First Posted Date: 2010-02-03

Last Posted Date: 2022-08-05

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 16

Registration Number: NCT01061411

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇳🇱
Academ Zienkenhuis Bij De University, Amsterdam, Netherlands

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy